ProCE Banner Activity

Timing of Antibiotic Use During Immune Checkpoint Inhibitor Therapy and Clinical Outcomes in Patients With Urothelial Cancer

Slideset Download
Conference Coverage
Use of antibiotics 30 days before or after starting ICI therapy in patients with advanced urothelial cancer associated with worse survival outcomes in this retrospective, exploratory analysis.

Released: June 05, 2020

Expiration: June 04, 2021

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono